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Abstract. Background: In phase 2 trials, telaprevir, a hepatitis C
virus (HCV) genotype 1 protease inhibitor, in combination with
peginterferon-ribavirin, as compared with peginterferon-ribavirin
alone, has shown improved efﬁcacy, with potential for shortening
the duration of treatment in a majority of patients.
Methods: In this international, phase 3, randomized, double-blind,
placebo-controlled trial, we assigned 1088 patients with HCV geno-
type 1 infection who had not received previous treatment for the
infection to one of three groups: a group receiving telaprevir com-
bined with peginterferon alfa-2a and ribavirin for 12 weeks (T12PR
group), followed by peginterferon-ribavirin alone for 12 weeks if
HCV RNA was undetectable at weeks 4 and 12 or for 36 weeks if
HCV RNA was detectable at either time point; a group receiving
telaprevir with peginterferon-ribavirin for 8 weeks and placebo
with peginterferon-ribavirin for 4 weeks (T8PR group), followed
by 12 or 36 weeks of peginterferon-ribavirin on the basis of the
same HCV RNA criteria; or a group receiving placebo with peginter-
feron-ribavirin for 12 weeks, followed by 36 weeks of peginterfer-
on-ribavirin (PR group). The primary end point was the
proportion of patients who had undetectable plasma HCV RNA
24 weeks after the last planned dose of study treatment (sustained
virologic response).
Results: Signiﬁcantly more patients in the T12PR or T8PR group
than in the PR group had a sustained virologic response (75% and
69%, respectively, vs. 44%; p <0.001 for the comparison of the
T12PR or T8PR group with the PR group). A total of 58% of the
patients treated with telaprevir were eligible to receive 24 weeks
of total treatment. Anemia, gastrointestinal side effects, and skinJournal of Hepatology 20
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alone. The overall rate of discontinuation of the treatment regimen
owing to adverse events was 10% in the T12PR and T8PR groups
and 7% in the PR group.
Conclusions: Telaprevir with peginterferon-ribavirin, as compared
with peginterferon-ribavirin alone, was associated with signiﬁcantly
improved rates of sustained virologic response in patients with HCV
genotype 1 infection who had not received previous treatment, with
only 24 weeks of therapy administered in the majority of patients.
(Funded by Vertex Pharmaceuticals and Tibotec; ADVANCE Clinical-
Trials.gov number, NCT00627926)
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Abstract. Background: Up to 60% of patients with hepatitis C virus
(HCV) genotype 1 infection do not have a sustained virologic response
to therapy with peginterferon alfa plus ribavirin.
Methods: In this randomized, phase 3 trial, we evaluated the addi-
tion of telaprevir to peginterferon alfa-2a plus ribavirin in patients
with HCV genotype 1 infection who had no response or a partial
response to previous therapy or who had a relapse after an initial
response. A total of 663 patients were assigned to one of three
groups: the T12PR48 group, which received telaprevir for 12 weeks
and peginterferon plus ribavirin for a total of 48 weeks; the lead-
in T12PR48 group, which received 4 weeks of peginterferon plus
ribavirin followed by 12 weeks of telaprevir and peginterferon plus
ribavirin for a total of 48 weeks; and the control group (PR48),
which received peginterferon plus ribavirin for 48 weeks. The pri-
mary end point was the rate of sustained virologic response, which
was deﬁned as undetectable HCV RNA 24 weeks after the last
planned dose of a study drug.
Results: Rates of sustained virologic response were signiﬁcantly
higher in the two telaprevir groups than in the control group among
patients who had a previous relapse (83% in the T12PR48 group, 88%
in the lead-in T12PR48 group, and 24% in the PR48 group), a partial
response (59%, 54%, and 15%, respectively), and no response (29%,
33%, and 5%, respectively) (p <0.001 for all comparisons). Grade 311 vol. 55 j 1457–1460
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Fig. 1. Advance study design and results. (A) N = 350 planned subjects per arm
(1050 planned subjects total). Treatment arms were (a) Telaprevir 750 mg q8 h in
combination with PEG-IFN alfa-2a and RBV for 8 weeks, followed by additional
weeks of standard of care; (b) Telaprevir 750 mg q8 h in combination with PEG-
IFN alfa-2a and RBV for 12 weeks, followed by additional weeks of standard of
care; (c) PEG-IFN alfa-2a and RBV for 48 weeks (control arm). Patients in
telaprevir arms achieving an extended rapid viral response (eRVR, undetectable
HCV RNA at weeks 4 and 12) received a total of 24 weeks of therapy while those
who did not received a total of 48 weeks of therapy [5]. (B) A signiﬁcantly greater
proportion of patients achieved SVR with 12-week and 8-week telaprevir-based
combination regimens (75% and 69%, respectively) compared with PEG-IFN alfa-
2a and RBV 48 weeks control arm (44%, p <0.001) [5].
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adverse events (mainly anemia, neutropenia, and leukopenia) were
more frequent in the telaprevir groups than in the control group
(37% vs. 22%).
Conclusions: Telaprevir combined with peginterferon plus ribavirin
signiﬁcantly improved rates of sustained virologic response in
patients with previously treated HCV infection, regardless of whether
there was a lead-in phase. (Funded by Tibotec and Vertex Pharma-
ceuticals; REALIZE ClinicalTrials.gov number, NCT00703118.)
 2011 European Association for the Study of the Liver. Published
by Elsevier B.V.
New direct acting antivirals (DAA), such as protease and poly-
merase inhibitors, are currently under development [1]. For
the treatment of genotype 1 chronic hepatitis C, in both treat-
ment-naïve and treatment-experienced patients, two NS3/4A
protease inhibitors, telaprevir, and boceprevir, were approved
in Europe and the United States in 2011 for use in combination
with pegylated interferon and ribavirin. In a previous article, we
discussed results obtained with Boceprevir (developed by the
companies Merk/Schering Plough) in both treatment-naïve and
treatment-experienced patients [2–4]. Interesting data were
reported with Telaprevir (developed by the companies Vertex
and Tibotec) in both treatment-naïve [5–6] and treatment-expe-
rienced patients [7]. This article is discussing the two major
phase III clinical trials published recently (Advance [5] and Real-
ize [7]).
The Advance study (Fig. 1A and B) is a 3-arm double-blind, ran-
domized, placebo-controlled Phase 3 study assessing efﬁcacy and
safety of two telaprevir-based response-guided regimens com-
pared with PEG-IFN alfa-2a and RBV in treatment-naïve patients
with chronic genotype 1 HCV infection [5]. The trial design is pre-
sented in Fig. 1A. A signiﬁcantly greater proportion of patients
achieved SVR with the 12-week and 8-week telaprevir-based
combination regimens (75% and 69%, respectively) compared
with the PEG-IFN alfa-2a and RBV 48 weeks control arm (44%,
p <0.001) (Fig. 1B).
The most common (>25%) adverse events in the telaprevir
arms were fatigue, pruritus, nausea, headache, anemia, rash,
inﬂuenza-like illness, insomnia, pyrexia, and diarrhea. Discontin-
uation of treatment due to adverse events occurred in 7% and 8%
in telaprevir regimens and 4% in PEG-IFN alfa-2a and RBV; it was
caused by rash in 0.5%, 1.4%, and 0.0%, and it was due to anemia
in 3.3%, 0.8%, and 0.6% in telaprevir 8 weeks in combination with
PEG-IFN alfa-2a and RBV, telaprevir 12 weeks with PEG-IFN alfa-
2a and RBV; and control arms, respectively.
Finally, the telaprevir-based therapy improved SVR rates in
genotype 1 treatment-naive patients. A 12-week telaprevir-based
regimen demonstrated a better beneﬁt:risk proﬁle than an
8-week regimen. With response guided therapy, nearly two-
thirds naïve patients were eligible for a 24-week treatment, and
attained high rates of SVR. Discontinuation of the treatment
regimen due to rash was minimized by stopping medication
sequentially.
The Illuminate study is a Phase 3 open-label study evaluating
patients randomized to two durations of therapy among those
who achieved extended rapid viral response (eRVR) [6].
Five hundred and forty HCV genotype 1 treatment-naïve
patients were treated with telaprevir (12 weeks, 750 mg po
q8 h) with PEG-IFN alfa2a and RBV. Patients who achieved
eRVR (undetectable HCV RNA at weeks 4 and 12) were ran-
domized at week 20 to continue receiving PEG-IFN alfa2a
Open access under CC BY-NC-ND license.1458 Journal of Hepatology 2011and RBV for 24 or 48 weeks of total treatment. Patients not
achieving eRVR were assigned 48 weeks of treatment [6]. 72%
(n = 389) of patients achieved RVR; 65.2% (n = 352) of patients
achieved eRVR. 322 (59.6%) patients were randomized (1:1) to
either a 24- or 48-weeks arm. SVR was 92% among patients
randomized to 24 weeks (n = 162) and 87.5% (D4.5%, 2-sided
95% C.I. = 2.1% to +11.1%) among patients randomized to
48 weeks (n = 160). Overall, SVR was 71.9% (ITT analysis). SVR
was 92% among patients randomized to 24 wks (n = 162).
SVR was 87.5% (D4.5%, 2-sided 95% C.I. = 2.1% to +11.1%)
among patients randomized to 48 weeks (n = 160). 36 patients
(6.7%) discontinued treatment due to virologic failure. 94
patients (17.4%) had permanent discontinuation of all study
drugs for adverse events. Fatigue (n = 22) and anemia (n = 12)
were the most common adverse events leading to discontinua-
tion. Treatment discontinuation due to anemia and rash were 3
(0.6%) and 6 (1.1%) patients, respectively, during the telaprevir
treatment phase.
Finally, among patients who achieved eRVR, a 24-week tela-
previr-based regimen was non-inferior to 48-week telaprevir-
based regimen (92% SVR compared to 87.5%). Response-guided
treatment led to 71.9% SVR overall and nearly two-thirds of the
patients were eligible for shorter duration of treatment. Perma-
nent discontinuation of all study drugs due to adverse events
occurred in 17.4% of patients. These results support response-
guided therapy for telaprevir-based regimens in treatment-naïve
patients.vol. 55 j 1457–1460
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ig. 2. Realize study design and results. (A) There were two telaprevir-based
rms (simultaneous and delayed start) and one control arm. Patients were
ndomized 2:2:1 to the two telaprevir arms and the control arm, respectively. As
all Phase 3 studies of telaprevir, patients received no more than 12 weeks of
laprevir given in combination with pegylated interferon and ribavirin. In this
udy, the telaprevir arms included 12 weeks of telaprevir in combination with
egylated-interferon and ribavirin with 36 weeks of pegylated-interferon and
bavirin alone for a total of 48 weeks of treatment. One of the telaprevir
eatment arms was designed to evaluate whether there was any further
provement in viral cure rates when delaying the start of telaprevir by four
eeks, during which time, patients received four weeks of pegylated-interferon
nd ribavirin alone, compared to a simultaneous start [7]. Randomization was
ratiﬁed by viral load and prior response. Stopping rules applied for TVR (Weeks
, 6, and 8 for T12/PR48; Weeks 8, 10, and 12 for Li T12/PR48) and Peg-IFN/RBV
eeks 12, 24, and 36 for T12/PR48; Weeks 16, 24 and 36 for Li T12/PR48) Peg-
N: Peg-IFN alfa-2a = 180 lg/week; RBV = 1000–1200 mg/day; TVR = 750 mg
very 8 h. (B) SVR rates for the telaprevir simultaneous start arm and the delayed
art arm were 64% and 66%, respectively, overall, based on an intent-to-treat
TT) analysis. For the primary analysis, the SVR rates for the telaprevir
multaneous start arm, delayed start arm and control arm, respectively, were
3%, 88%, and 24% in relapsers (p <0.001); 59%, 54%, and 15% in partial responders,
<0.001); and 29%, 33%, and 5% in null responders, (p <0.001) [7].
JOURNAL OF HEPATOLOGY
What have we learned?
First, duration of therapy should be shortened in naive genotype 1
patients who achieved eRVR
A major information from the telaprevir studies, is that approxi-
mately two-thirds of patients achieved RVR and remain HCV RNA
negative through 24 weeks and beneﬁt from 24 weeks of treat-
ment. Treatment-naïve patients with cirrhosis who have unde-
tectable HCV-RNA at weeks 4 and 12 may beneﬁt from an
additional 36 weeks of peginterferon alfa and ribavirin (48 weeks
total).
Second, knowledge of the stopping rules is important
Discontinuation of therapy is recommended in all patients with
HCV-RNA levels of greater than or equal to 1000 IU/ml at treat-
ment week 4 or 12; or conﬁrmed detectable HCV-RNA levels at
treatment Week 24. Patients may develop treatment-emergent
resistance substitutions.
Can either interferon be utilized with either protease inhibitor?
Probably yes. In a prospective, multicenter, randomized, open-
label, phase 2 clinical trial study, including 161 HCV genotype 1
patients, a high proportion (>80%) of patients achieved an SVR
regardless of the telaprevir dosing frequency (q8 h or q12 h) or
type of peginterferon alfa used (alfa-2a or alfa-2b) [8]. Each pegy-
lated interferon provides approximately the same SVR (4). It
might be that either interferon could be utilized with either pro-
tease inhibitor; however we need more information regarding
this issue.
The Realize study is a phase 3, randomized, double-blind, pla-
cebo-controlled study conducted in 662 genotype 1 chronic hep-
atitis C patients who did not achieve an SVR after at least one
prior treatment with IFN-based therapy [7]. Trial design is pre-
sented in Fig. 2A. There were two telaprevir-based arms (simulta-
neous and delayed start) and one control arm. As in all Phase 3
studies of telaprevir, patients received no more than 12 weeks
of telaprevir given in combination with pegylated interferon
and ribavirin. One of the telaprevir treatment arms was designed
to evaluate whether there was any further improvement in viral
cure rates when delaying the start of telaprevir by four weeks,
during which time patients received four weeks of pegylated-
interferon and ribavirin alone, compared to a simultaneous start.
The SVR rates between these two arms were similar and there
was no clinical beneﬁt to the telaprevir delayed start treatment
arm in any of the subgroups of patients. SVR rates for the telapre-
vir simultaneous start arm and the delayed start arm were 64%
and 66%, respectively, overall, based on an intent-to-treat (ITT)
analysis (Fig. 2B). For the primary analysis, the SVR rates for
the telaprevir simultaneous start arm, delayed start arm and con-
trol arm, respectively, were 83%, 88%, and 24% in relapsers
(p <0.001); 59%, 54%, and 15% in partial responders, (p <0.001);
and 29%, 33%, and 5% in null responders, (p <0.001) (Fig. 2B).
Prior relapsers might be treated for a duration of 24 weeks if
they achieved eRVR. Among prior relapsers, 76% (218/286)
achieved an eRVR and of those 95% (208/218) achieved an SVR.
Partial responders and non responders will be treated for
48 weeks. Null responders may wait for future combination
treatment. The mechanisms of non response to interferon areJournal of Hepatology 2011F
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might partially restore IFN responsiveness [9].
Finally, a major breakthrough has been achieved with triple
therapy when telaprevir is added to pegylated interferon and
ribavirin. Realize the Advance in HCV treatment, but remain cau-
tious. In genotype 1 naïve and experienced patients, standard of
care is currently the triple therapy with telaprevir or boceprevir,
with PEG-IFN plus ribavirin.
This led to major expectancies but also caution. There will be
major educational needs to achieve good clinical use of treat-
ment. First, knowledge of treatment response predictors will
include genotype 1 subtype, and also all previously known
predictors (RVR, etc.). Power of IL28B polymorphisms testing tovol. 55 j 1457–1460 1459
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predict SVR for triple therapy is not completely evaluated cur-
rently and cannot be recommended at this time. Naïve patients
who achieved eRVR beneﬁt from a shorter duration treatment.
Treatment has to be well explained and simpliﬁed. Second, it will
be important to focus on compliance. In addition to PEG-IFN and
ribavirin, telaprevir is administered orally at a dose of 750 mg
three times daily (to be taken with food and at an interval of
7–9 h between doses) in two capsules of 375 mg each. Compli-
ance will be an issue, since poor compliance is associated with
failure and resistance.
Third, management of side effects and treatment dose adapta-
tion will be important. The main side effects observed with tela-
previr are skin lesions, including rash and pruritus, and anemia.
In the Advance study, rash was more frequently observed in the
12-week telaprevir arm than in the control arm (56% vs. 37%,
respectively) [5]. Rash was also more frequent in the telaprevir
arm in the REALIZE study (37% and 36% in the telaprevir arms
vs. 19% in the control arm) [7]. Approximately 90% of all rashes
were mild or moderate (grades 1 and 2), whereas 6% of patients
experienced severe (grade 3) rash, leading to telaprevir discontin-
uation [5]. Grade 3 to 4 cutaneous lesions require immediate
treatment discontinuation and immediate consultation with
experienced dermatologists. Frequent physical examinations
together with laboratory testing for anemia to adapt dosing will
be needed. Last but not least, measurements of HCV RNA for
monitoring drug resistance will be mandatory. HCV RNA assays
based on real-time PCR will have to be done frequently. A viral
breakthrough in a compliant patient is very likely to be drug
resistance and is a stopping rule.
In the future, we do hope that once several DDAs become
available, treatment strategies will include a combination of
several drugs with different mechanisms of action (protease1460 Journal of Hepatology 2011inhibitors plus polymerase inhibitors) that could hopefully result
in IFN- and/or ribavirin sparing regimens leading to additive
potency, lacking cross resistance and with a good safety proﬁle.Conﬂict of interest
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